tetano
Editor, Senior Moderator
Aging (Albany NY)
. 2020 Aug 29;12.
doi: 10.18632/aging.103581. Online ahead of print.
Early coagulation tests predict risk stratification and prognosis of COVID-19
Lili Luo[SUP] 1 2 [/SUP], Min Xu[SUP] 1 2 [/SUP], Mengyi Du[SUP] 1 2 [/SUP], Haiming Kou[SUP] 1 2 [/SUP], Danying Liao[SUP] 1 2 [/SUP], Zhipeng Cheng[SUP] 1 2 [/SUP], Heng Mei[SUP] 1 2 [/SUP], Yu Hu[SUP] 1 2 [/SUP]
Affiliations
Abstract
The ongoing outbreak of Coronavirus Disease 2019 (COVID-19) is hitting the world hard, but the relationship between coagulation disorders and COVID-19 is still not clear. This study aimed to explore whether early coagulation tests can predict risk stratification and prognosis. PubMed, Web of Science, Cochrane Library, and Scopus were searched electronically for relevant research studies published up to March 24, 2020, producing 24 articles for the final inclusion. The pooled standard mean difference (SMD) of coagulation parameters at admission were calculated to determine severe and composite endpoint conditions (ICU or death) in COVID-19 patients. Meta-analyses revealed that platelet count was not statistically related to disease severity and composite endpoint; elevated D-dimer correlated positively with disease severity (SMD 0.787 (0.277-1.298), P= 0.003, I[SUP]2[/SUP]= 96.7%) but had no significant statistical relationship with composite endpoints. Similarly, patients with prolonged prothrombin time (PT) had an increased risk of ICU and increased risk of death (SMD 1.338 (0.551-2.125), P = 0.001, I[SUP]2[/SUP] = 92.7%). Besides, increased fibrin degradation products (FDP) and decreased antithrombin might also mean the disease is worsening. Therefore, early coagulation tests followed by dynamic monitoring is useful for recognizing coagulation disorders accompanied by COVID-19 and guiding timely therapy to improve prognosis.
Keywords: COVID-19; blood coagulation disorders; meta-analysis; prognosis; risk.
. 2020 Aug 29;12.
doi: 10.18632/aging.103581. Online ahead of print.
Early coagulation tests predict risk stratification and prognosis of COVID-19
Lili Luo[SUP] 1 2 [/SUP], Min Xu[SUP] 1 2 [/SUP], Mengyi Du[SUP] 1 2 [/SUP], Haiming Kou[SUP] 1 2 [/SUP], Danying Liao[SUP] 1 2 [/SUP], Zhipeng Cheng[SUP] 1 2 [/SUP], Heng Mei[SUP] 1 2 [/SUP], Yu Hu[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32860672
- DOI: 10.18632/aging.103581
Abstract
The ongoing outbreak of Coronavirus Disease 2019 (COVID-19) is hitting the world hard, but the relationship between coagulation disorders and COVID-19 is still not clear. This study aimed to explore whether early coagulation tests can predict risk stratification and prognosis. PubMed, Web of Science, Cochrane Library, and Scopus were searched electronically for relevant research studies published up to March 24, 2020, producing 24 articles for the final inclusion. The pooled standard mean difference (SMD) of coagulation parameters at admission were calculated to determine severe and composite endpoint conditions (ICU or death) in COVID-19 patients. Meta-analyses revealed that platelet count was not statistically related to disease severity and composite endpoint; elevated D-dimer correlated positively with disease severity (SMD 0.787 (0.277-1.298), P= 0.003, I[SUP]2[/SUP]= 96.7%) but had no significant statistical relationship with composite endpoints. Similarly, patients with prolonged prothrombin time (PT) had an increased risk of ICU and increased risk of death (SMD 1.338 (0.551-2.125), P = 0.001, I[SUP]2[/SUP] = 92.7%). Besides, increased fibrin degradation products (FDP) and decreased antithrombin might also mean the disease is worsening. Therefore, early coagulation tests followed by dynamic monitoring is useful for recognizing coagulation disorders accompanied by COVID-19 and guiding timely therapy to improve prognosis.
Keywords: COVID-19; blood coagulation disorders; meta-analysis; prognosis; risk.